Daiichi Sankyo (OTCMKTS:DSNKY) Updates FY 2026 Earnings Guidance

Daiichi Sankyo (OTCMKTS:DSNKY) updated its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.870-0.870 for the period, compared to the consensus EPS estimate of 1.040. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $13.4 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DSNKY shares. Jefferies Financial Group downgraded Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday. Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, Daiichi Sankyo presently has an average rating of “Hold”.

Daiichi Sankyo Stock Performance

OTCMKTS:DSNKY opened at $18.23 on Friday. The firm has a 50 day simple moving average of $16.52 and a 200-day simple moving average of $17.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. The firm has a market cap of $33.96 billion, a PE ratio of 19.39, a P/E/G ratio of 3.10 and a beta of -0.17. Daiichi Sankyo has a 1-year low of $14.98 and a 1-year high of $27.50.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities analysts expect that Daiichi Sankyo will post 0.96 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.